Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Clinical Trials, Studies & Reports Financials Regulatory May 14, 2026

Glucotrack, Inc. reported its first quarter 2026 financial results, showing progress in its continuous blood glucose monitoring (CBGM) technology alongside increased research and administrative expenses. The company submitted an Investigational Device Exemption (IDE) application to the FDA for U.S. clinical trials and published supportive studies in reputable journals. Despite a net loss reduction year-over-year, cash reserves declined, though they expect enough runway to initiate clinical trials in the third quarter of 2026.

Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology